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Abstract 
Introduction: Listeria species are susceptible to most antibiotics. However, over the last decade, increasing reports of multidrug-resistant 
Listeria spp. from various sources have prompted public health concerns. The objective of this study was to characterize the antibiotic 
susceptibility of Listeria spp. and the genetic mechanisms that confer resistance.  
Methodology: Forty-six Listeria spp. isolates were studied, and their minimal inhibitory concentrations of antibiotics were determined by 
microdilution using Sensititre standard susceptibility MIC plates. The isolates were screened for the presence of gyrA, parC, lde, lsa(A), 
lnu(A), and mprF by PCR, and the amplified genes were sequenced.  
Results: All isolates were susceptible to penicillin, ampicillin, tetracycline, erythromycin, and carbapenems. Resistance to clindamycin, 
daptomycin, and oxacillin was found among L. monocytogenes and L. innocua, and all species possessed at least intermediate resistance to 
fluoroquinolones. GyrA, parC, and mprF were detected in all isolates; however, mutations were found only in gyrA sequences. A high 
daptomycin MIC, as reported previously, was observed, suggesting an intrinsic resistance of Listeria spp. to daptomycin.  
Conclusions: These results are consistent with reports of emerging resistance in Listeria spp. and emphasize the need for further genotypic 
characterization of antibiotic resistance in this genus. 
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Introduction 
The genus Listeria is characterized by Gram-
positive, facultatively anaerobic rods that are widely 
distributed in the environment [1]. Eight species are 
currently described in the Listeria genus: L. 
monocytogenes, L. innocua, L. seeligeri, L. 
welshimeri, L. ivanovii, L. grayi, L. marthii, and L. 
rocourtiae [2]. Only L. monocytogenes and L. ivanovii 
are considered to be pathogenic to animals and 
humans [1]; however, instances of human listeriosis 
due to L. seeligeri and L. innocua infection have been 
reported [3,4]. 
Listeriosis represents a public health concern; its 
fatality rate can be as high as 30%. The disease 
primarily affects the elderly, neonates, and 
immunocompromised individuals, which includes an 
increasing population of cancer and HIV-positive 
patients [1,5,6]. A positive outcome for listeriosis 
depends on the early administration of antibiotics. The 
standard treatment remains the application of high 
doses of a beta-lactam antibiotic (ampicillin or 
amoxicillin) alone or in combination with gentamicin; 
sulfamethoxazole is generally used in the case of beta-
lactam intolerance [7]. 
Most Listeria species are susceptible to all 
antibiotics except cephalosporins and fosfomycin, to 
which they are naturally resistant [8]. However, 
increasing reports of Listeria strains isolated from 
various sources that are resistant to penicillin, 
ampicillin, tetracycline, streptomycin, clindamycin, 
and even oxacillin and vancomycin represent a major 
public health concern [9-11]. The genetic mechanisms 
responsible for these resistances are an important 
research topic, given that L. monocytogenes can 
acquire resistance genes from, and transfer them to, 
enterococci, staphylococci, and streptococci [12,13].  
Moreno et al. – Listeria antibiotic resistance                              J Infect Dev Ctries 2014; 8(4):416-423. 
417 
The purpose of this study was to characterize the 
antibiotic susceptibility profiles of Listeria spp. 
isolated from slaughterhouse environments and pork 
and human infections, and the genetic mechanisms 
that confer resistance. 
 
Methodology 
Bacterial strains 
Forty-six Listeria spp. isolates were studied. Of 
these, 25 were isolated from pork and slaughterhouse 
environments (15 isolates of L. monocytogenes and 10 
of L. innocua), 11 isolates of L. monocytogenes were 
from human infections, two isolates were L. ivanovii, 
two isolates were L. seeligeri, two isolates were L. 
welshimeri, and four were controls (L. monocytogenes 
ATCC 19115 and ATCC 19111, and L. innocua 
ATCC 33090 and CLIP 12612) (Table 1). The 
environmental and pork isolates had been previously 
isolated as described by Moreno et al. [14]; the other 
Listeria spp. isolates were obtained from the Public 
Health Laboratory (School of Public Health, 
University of Sao Paulo) collection. Environmental 
and pork isolates originated from different samples 
from slaughterhouse environments and carcasses from 
Sao Paulo state, and human isolates originated from 
different patients from various Brazilian states (Table 
1). 
All of the isolates were previously characterized 
by serotyping according to Seeliger and Höhne’s [15] 
protocol, the catalase test, motility, cultivation in 
selective agar ALOA (Biolife, Milano, Italy), and -
hemolysis on sheep blood agar. Species identity was 
confirmed using 16S rRNA analysis (data not shown). 
All isolates were stored in stock medium with glycerol 
at -80ºC. The isolates were reactivated in brain-heart 
infusion medium (BHI; BD-Difco, Franklin Lakes, 
USA) and plated on tryptone soy agar (TSA; Oxoid, 
Basingstoke, UK) to isolate pure colonies before use. 
 
Antibiotic susceptibility test 
Minimal inhibitory concentrations (MICs) of 
Listeria isolates were determined by microdilution, as 
recommended by the Clinical and Laboratory 
Standards Institute [16], using Sensititre standard 
susceptibility MIC plates ESB1F and GPALL1F 
(TREK Diagnostic Systems/Thermo Fisher Scientific, 
Waltham , USA), which contained over 32 antibiotics 
at a full range of MICs, including penicillin (0.06-8 
µg/mL), oxacillin (0.25-4 µg/mL), ampicillin (0.12-8 
µg/mL), cefazolin (8-16 µg/mL), cefepime (1-16 
µg/mL), cefotaxime (0.25-64 µg/mL), ceftazidime 
(0.25-128 µg/mL), ceftriaxone (1-128 µg/mL), 
cefoxitin (4-64 µg/mL), cefpodoxime (0.25-32 
µg/mL), cephalothin (8-16 µg/mL), imipenem (0.5-16 
µg/mL), meropenem (1-8 µg/mL), vancomycin (0.25-
32 µg/mL), daptomycin (0.5-4 µg/mL), gentamycin 
(2-16 µg/mL), erythromycin (0.25-4 µg/mL), 
tetracycline (2-16 µg/mL), moxifloxacin (0.25-4 
µg/mL), levofloxacin (0.25-4 µg/mL), ciprofloxacin 
(1-2 µg/mL), nitrofurantoin (32-64 µg/mL), 
clindamycin (0.5-2 µg/mL), chloramphenicol (2-16 
µg/mL), rifampicin (0.5-4 µg/mL), linezolid (1-8 
µg/mL), tigecycline (0.03-0.5 µg/mL), 
quinupristin/dalfopristin (0.5-4 µg/mL), 
trimethoprim/sulfamethoxazole (0.5/9.5-4/76 µg/mL), 
and piperacillin/tazobactam (4/4-64/4 µg/mL). The 
GPALL1F plate also included the D-test to assess 
erythromycin- and clindamycin-inducible resistance. 
MIC values were manually recorded. S. pneumoniae 
ATCC 49619 and S. aureus ATCC 29213 were used 
as quality control strains. The results were interpreted 
according to L. monocytogenes breakpoints for 
penicillin, ampicillin, and sulfamethoxazole [16], and 
the staphylococci criteria were used for the other 
tested antibiotics [17].  
 
PCR detection of antibiotic resistance genes 
Genomic DNA extraction was performed 
according to Ausubel et al.’s [18] protocol (CTAB). 
According to the antibiotic susceptibility results, 
the isolates were screened for fluoroquinolone 
resistance. The gyrA and parC genes, which encode 
subunits of DNA gyrase topoisomerase II and 
topoisomerase IV, and the lde gene, which encodes an 
efflux pump associated with fluoroquinolone 
resistance, were amplified using primer sequences 
from Godreuil et al. [19] and Romanova et al. [20], 
respectively. The isolates were also screened for 
clindamycin resistance. The lsa(A) and lnu(A) genes, 
which encode enzymes that inactivate clindamycin, 
were amplified using primer sequences from Singh 
and Murray [21] and Lina et al. [22], respectively. To 
amplify the mprF gene, which is linked to daptomycin 
resistance, primer sequences were designed based on 
the homologous gene Lmo1695 (mprF forward – 
TGCGGGTGGTCTTTACTTCC; mprF reverse – 
CGCGAGCAAGTGTGTTGAAA). 
PCR reactions and programs were primer specific, 
followed the recommendations of the respective 
authors, and were performed using an Eppendorf 
Mastercycler gradient thermocycler. Each reaction (25 
L) used 5 L of genomic DNA, MilliQ water, 10X 
PCR buffer, 1.5 mM MgCl2, 200 M of dNTPs 
(Fermentas Fermentas- Thermo Fisher Scientific Inc., 
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Waltham, USA), 200 M of each primer, and 1.25 U 
of Taq-DNA-polymerase (Promega, Fitchburg, USA). 
The amplified products were separated by 
electrophoresis in 1.5% agarose gels and stained with 
ethidium bromide (1 μg/mL). Molecular weight 
determinations were determined using the 1Kb Plus 
DNA Ladder (Fermentas Fermentas- Thermo Fisher 
Scientific Inc., Waltham, USA).  
 
Sequencing and analysis 
Amplified fragments were purified using the 
Illustra GFX PCR DNA and Gel Band Purification kit 
(GE Healthcare Little Chalfont, UK) and sequenced 
directly by Genomic Engenharia Molecular (Sao 
Paulo/SP, Brazil). The BIOEDIT Sequence Alignment 
Editor 7.0.9 [23] was used for sequence analysis. The 
sequences of the gyrA and parC quinolone resistance-
determining regions (QRDRs) were compared to 
sequences from isolates with resistant, intermediate, 
and sensitive fluoroquinolone profiles and to 
previously published Listeria spp., E. coli, S. aureus, 
and S. pneumoniae QRDR sequence accessions from 
GenBank (NCBI, Bethesda, USA). For the analysis of 
mprF, sequences from daptomycin-susceptible and 
daptomycin-resistant isolates were compared to search 
for mutations that could explain the resistance 
phenotype. 
 
Nucleotide sequence accession numbers 
All DNA sequences from this study were 
deposited in GenBank under accession numbers 
KC808584 to KC808600.  
 
Results 
The antibiotic resistance of the Listeria species is 
shown in Table 2. All isolates were susceptible to 
penicillin, ampicillin, vancomycin, cephalothin, 
imipenem, and meropenem. Resistance to clindamycin 
and oxacillin was found among L. monocytogenes and 
L. innocua isolates and included L. monocytogenes 
isolates of human origin. It is noteworthy that 37% of 
the isolates were resistant to daptomycin, an antibiotic 
that was recently approved in Latin America and is 
specific for Gram-positive infections. Furthermore, all 
studied Listeria species presented at least intermediate 
resistance to ciprofloxacin, levofloxacin, or 
moxifloxacin. The antibiotic MIC ranges, MIC50 and 
MIC90, are summarized in Table 3. In contrast to 
resistance profiles observed in Europe and North 
America, all isolates were susceptible to tetracycline, 
erythromycin, rifampicin, and trimethoprim-
sulfamethoxazole. The only difference observed in the 
resistance frequencies among the human and 
environmental isolates was that all human isolates 
presented intermediate resistance to clindamycin (data 
not shown). 
The gyrA and parC genes were detected in all of 
the isolates, which was expected because these are 
constitutive genes encoding subunits of DNA gyrase 
topoisomerase II and topoisomerase IV, respectively. 
MprF was also detected in all of the isolates, whereas 
82.6% (38/46) of Listeria isolates were positive for 
lde. Lsa(A) and lnu(A) were not detected in any of the 
isolates. No differences were observed in the 
phenotypic or genotypic resistance profiles of the 
Listeria species. 
Figure 1. Schematic representation of gyrA QRDR sequences of the Listeria spp. isolates, E. coli, S. aureus, and S. pneumoniae. The 
codons are numbered according to the L. monocytogenes sequence, and residues that differ among the sequences are highlighted in bold. 
L. mono: L. monocytogenes; L. inn: L. 
innocua; L. welsh: L. welshimeri; L. seel: L. 
seeligeri; L. ivan: L. ivanovii; S. pneum: S. 
pneumoniae 
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 Table 1. Source and phenotypic characteristics of Listeria spp. isolates used in this study 
Isolate Species Serotype Origin Site State Year 
Lm1 L. monocytogenes 1/2a Slaught 1 Floor SP 2008 
Lm2 L. monocytogenes 1/2b Slaught 1 Floor SP 2008 
Lm3 L. monocytogenes 4b Market 1 Floor SP 2008 
Lm21 L. monocytogenes 1/2a Slaught 1 Floor SP 2008 
Lm22 L. monocytogenes 1/2a Slaught 1 Floor SP 2008 
Lm23 L. monocytogenes 1/2a Slaught 1 Floor SP 2008 
Lm25 L. monocytogenes 1/2a Slaught 1 Floor SP 2008 
Lm26 L. monocytogenes 1/2a Slaught 1 Floor SP 2008 
Lm27 L. monocytogenes 1/2a Slaught 1 Floor SP 2008 
Lm28 L. monocytogenes 1/2a Market 2 Pork SP 2008 
Lm29 L. monocytogenes 1/2a Market 2 Pork SP 2008 
Lm30 L. monocytogenes 1/2a Market 2 Pork SP 2008 
Lm31 L. monocytogenes 1/2a Market 2 Pork SP 2008 
Lm4 L. monocytogenes 1/2a Market 2 Pork SP 2008 
Lm33 L. monocytogenes 1/2a Market 2 Pork SP 2008 
Lm34 L. monocytogenes 1/2a Human Blood DF 1989 
Lm35 L. monocytogenes 4b Human Blood RJ 2004 
Lm36 L. monocytogenes 4b Human Blood SP 1997 
Lm37 L. monocytogenes 4b Human CSF SP 1982 
Lm38 L. monocytogenes 1/2b Human CSF PR 1983 
Lm39 L. monocytogenes 1/2a Human Placenta PE 1978 
Lm39a L. monocytogenes 1/2a Human Placenta PE 1978 
Lm40 L. monocytogenes 1/2a Human Blood SP 1985 
Lm41 L. monocytogenes 4b Human CSF SP 1997 
Lm42 L. monocytogenes 4b Human CSF SP 1997 
Lm43 L. monocytogenes 1/2a Human CSF PR 1983 
Lin5 L. innocua 6a Market 1 Floor SP 2008 
Lin6 L. innocua 6a Slaught 2 Floor SP 2008 
Lin7 L. innocua 6a Slaught 2 Floor SP 2008 
Lin8 L. innocua 6a Slaught 2 Floor SP 2008 
Lin9 L. innocua 6a Slaught 2 Floor SP 2008 
Lin16 L. innocua 6a Slaught 1 Floor SP 2006 
Lin17 L. innocua 6a Slaught 1 Floor SP 2006 
Lin18 L. innocua 6a Slaught 1 Floor SP 2006 
Lin19 L. innocua 6a Slaught 1 Floor SP 2006 
Lin20 L. innocua 6a Slaught 1 Floor SP 2006 
Lwe12 L. welshimeri - CIP 8149 - - - 
Lwe49 L. welshimeri - - - - - 
Lse13 L. seeligeri - CIP 100100 - - - 
Lse14 L. seeligeri - - - - - 
Liv47 L. ivanovii - ATCC 19119 - - - 
Liv48 L. ivanovii - - - - - 
Lm10 L. monocytogenes 4b ATCC 19115 - - - 
Lm15 L. monocytogenes 1/2a ATCC 19111 - - - 
Lin11 L. innocua 6a ATCC 33090 - - - 
Lin46 L. innocua 6a CLIP 12612 - - - 
Lm: L. monocytogenes; Lin: L. innocua; Liv: L. ivanovii; Lwe: L. welshimeri; Lse: L. seeligeri; Slaught1: Slaughterhouse 1; Slaught2: Slaughterhouse 2; 
CSF: cerebrospinal fluid; SP: Sao Paulo; RJ: Rio de Janeiro; DF: Distrito Federal; PE: Pernambuco; PR: Paraná  
 
  
 
 
 
Table 2. Resistance profiles and MIC values of Listeria species by antibiotic - N (%) 
Antibiotic 
MIC (µg/mL) L. monocytogenes L. innocua L. welshimeri L. seeeligeri L. ivanovii 
Range 50% 90% I R I R I R I R I R 
Penicillin 0.06 - 1 0.25 0.5 0 0 0 0 0 0 0 0 0 0 
Oxacillin 0.5 - 8 2 4 0 5 (17.9) 0 6 (50.0) 0 0 0 1 (50.0) 0 0 
Ampicillin 0.12 - 1 0.12 0.5 0 0 0 0 0 0 0 0 0 0 
Cefazolin 8 8 8 0 0 0 0 0 0 0 0 0 0 
Cefepime 1 - 32 16 32 3 (10.7) 8 (28.6) 3 (25.0) 8 (64.3) 0 1 (50.0) 1 (50.0) 0 0 0 
Cefotaxime 0.25 - 128 8 64 3 (10.7) 6 (23.1) 3 (25.0) 6 (50.0) 1 (50.0) 0 
2 
(100.0) 
0 0 0 
Ceftazidime 4 - 256 256 256 0 
28 
(100.0) 
0 
12 
(100.0) 
0 
2 
(100.0) 
0 
2 
(100.0) 
0 1 (50.0) 
Ceftriaxone 1 - 256 16 128 8 (28.6) 7 (25.0) 5 (41.7) 7 (58.3) 1 (50.0) 0 
2 
(100.0) 
0 1 (50.0) 0 
Cephalothin 8 8 8 0 0 0 0 0 0 0 0 0 0 
Imipenem 0.5 0.5 0.5 0 0 0 0 0 0 0 0 0 0 
Meropenem 1 1 1 0 0 0 0 0 0 0 0 0 0 
Vancomycin 0.5 - 1 1 1 1 (3.6) 0 0 0 0 0 0 0 0 0 
Daptomycin 0.5 - 8 1 4 0 4 (14.3) - 10 (83.3) - 
2 
(100.0) 
- 1 (50.0) - 0 
Gentamycin 2 - 4 2 2 0 0 0 0 0 0 0 0 0 0 
Erythromycin 0.25 - 0.5 0.25 0.25 0 0 0 0 0 0 0 0 0 0 
Tetracycline 2 2 2 0 0 0 0 0 0 0 0 0 0 
Moxifloxacin 0.5 - 2 1 1 13 (46.4) 1 (3.6) 8 (64.3) 0 0 0 
2 
(100.0) 
0 1 (50.0) 0 
Levofloxacin 1 - 4 2 2 20 (71.4) 0 10 (83.3) 0 1 (50.0) 0 1 (50.0) 1 (50.0) 2 (100.0) 0 
Ciprofloxacin 1 - 4 2 4 19 (67.9) 2 (7.1) 10 (83.3) 1 (8.3) 1 (50.0) 0 0 
2 
(100.0) 
1 (50.0) 0 
Nitrofurantoin 32 - 128 64 128 9 (32.1) 16 (57.1) 6 (50.0) 5 (41.7) 
2 
(100.0) 
0 1 (50.0) 1 (50.0) 2 (100.0) 0 
Clindamycin 0.5 - 4 2 4 24 (85.7) 3 (10.7) 6 (50.0) 6 (50.0) 
2 
(100.0) 
0 
2 
(100.0) 
0 1 (50.0) 0 
Chloramphenicol 2 - 16 8 16 2 (7.1) 0 4 (33.3) 0 0 0 1 (50.0) 0 0 0 
Rifampicin 0.5 0.5 0.5 0 0 0 0 0 0 0 0 0 0 
Quinuptn/Dalfoptn 0.5 - 2 1 1 0 0 1 (8.3) 0 0 0 0 0 0 0 
Linezolid 1 - 4 2 4 - 0 - 0 - 0 - 0 - 0 
Trimetop/Sulfametx 0.5/9.5 0.5/9.5 0.5/9.5 - 0 - 0 - 0 - 0 - 0 
Pipe/Tazo 4/4 4/4 4/4 - 0 - 0 - 0 - 0 - 0 
Tigecycline 0.03 - 0.12 0.06 0.06 - 0 - 0 - 0 - 0 - 0 
 
I: intermediate; R: resistant; Quinuptn/Dalfoptn: Quinupristin/Dalfopristin; Trimetop/Sulfametx: Trimethoprim/Sulfamethoxazole; Pipe/Tazo: Piperacillin/Tazobactam 
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The QRDR sequences of gyrA and parC from 
Listeria isolates with resistant, intermediate, and 
sensitive fluoroquinolone profiles were analyzed and 
compared to previously published sequences to search 
for mutations that could explain these resistance 
profiles. All of the Listeria gyrA QRDR sequences, 
including those that were previously published, 
contained the mutations Thr84Ser, Phe88Asp / 
Phe88Glu and Met117Ser / Met117Gly when 
compared to E. coli, S. aureus, and S. pneumoniae 
sequences (Figure 1). No differences were identified in 
the parC or mprF sequences from daptomycin-
susceptible and daptomycin-resistant isolates.  
 
Discussion 
The results of this study suggest the presence of a 
high level of resistance to clindamycin, daptomycin, 
and fluoroquinolone in Listeria spp. Although natural 
resistance to third- and fourth-generation 
cephalosporins was observed, the tested Listeria 
isolates were susceptible to the antibiotics that are 
currently used to treat listeriosis (i.e., penicillin, 
ampicillin, gentamycin, and trimethoprim-
sulfamethoxazole); consequently, these isolates do not 
represent any risk when these traditional treatments 
are used. However, certain L. monocytogenes, L. 
innocua, L. seeligeri, and L. welshimeri isolates were 
resistant to oxacillin, clindamycin, and daptomycin, 
which are antibiotics that are widely used in hospitals 
to treat Gram-positive infections [10]. This study 
confirms the emergence of Listeria spp. from different 
origins that are resistant to one or more antibiotics. 
Resistance to erythromycin, rifampicin, 
trimethoprim-sulfamethoxazole and, particularly, 
tetracycline, was not observed in the studied isolates. 
This resistance profile is relatively common in Europe 
and North America [11,24,25] and is consistent with 
the identification of the tet, aad, and erm resistance 
genes in Listeria spp. [13]. In Brazil, this resistance 
profile has not been commonly observed, and Listeria 
isolates are susceptible to most antibiotics [26-28]. For 
this reason, the study of antibiotic resistance in 
Listeria has not progressed to the point that the 
molecular mechanisms of resistance should receive 
significant attention. However, the emergence of 
clindamycin, oxacillin, and fluoroquinolone resistance 
is noteworthy [28,29] and demands attention due to 
the risk of increasing multidrug resistance in Listeria 
and the possibility of its transference to other bacteria. 
The only resistance genes that were detected in 
this study were related to fluoroquinolone and 
daptomycin resistance. Fluoroquinolone resistance in 
Gram-positive bacteria is usually related to mutations 
in the gyrA and parC genes, especially in the QRDRs, 
because these genes encode subunits of DNA gyrase 
topoisomerase II and topoisomerase IV, which are 
targets of fluoroquinolones. The resistance can also 
result from the action of efflux pumps that actively 
export the antibiotic, such as lde. In the present study, 
the gyrA sequences presented mutations that were 
previously described by Lampidis et al. [30], who only 
differentiated the gyrA QRDR of Listeria from those 
of other bacteria. Because these mutations are present 
in all Listeria sequences of both susceptible and 
resistant isolates, it is not possible to confirm their role 
in the development of resistance; however, they 
represent residues that are commonly associated with 
fluoroquinolone resistance [31]. No differences were 
identified in the parC sequences; however, little 
information is available regarding parC mutations in 
Listeria that are related to quinolone resistance.  
The lde sequences also presented no differences. 
Despite the fact that the lde efflux pump is associated 
with fluoroquinolone resistance in Gram-positive 
bacteria, lde appears to be ubiquitous in L. 
monocytogenes and, therefore, its detection is not 
sufficient to confirm its role in the development of 
resistance. Further studies that use efflux pump 
inhibitors, such as reserpine, should be developed to 
determine the origin of fluoroquinolone resistance in 
these isolates. Additionally, the possibility that lde 
hyperexpression could lead to fluoroquinolone 
resistance [20] should be studied to enhance our 
knowledge of the possible mechanisms of quinolone 
resistance in Listeria. 
The gene mprF was detected in isolates that were 
susceptible and resistant to daptomycin, and no 
differences were identified in the resulting sequences. 
Daptomycin resistance has already been described in 
Staphylococcus spp. and Enterococcus spp. to involve 
four genes (including mprF) that have homologs in L. 
monocytogenes [32]. Although few studies have tested 
Listeria for susceptibility to daptomycin, a high 
daptomycin MIC (4 mg/L) has been reported in 
clinical isolates of L. monocytogenes. Nonetheless, the 
mechanism of this resistance has not been elucidated 
[33]. These results could indicate an intrinsic 
resistance of Listeria spp. to daptomycin.  
Because the mechanism of clindamycin activity is 
similar to that of erythromycin and chloramphenicol, 
cross-resistance of these compounds has 
unsurprisingly been observed [34]. However, the 
present study reports only clindamycin resistance and 
found negative results for erythromycin- and 
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clindamycin-inducible resistance. These results 
corroborate the theory of a specific enzyme that 
inactivates clindamycin, as previously described for 
Staphylococcus spp. The genes lsa(A) and lnu(A) 
appear to be related to this type clindamycin resistance 
in Enterococcus spp. and Staphylococcus spp. [21,22]. 
Although lsa(A) and lnu(A) were not detected, the 
clindamycin resistance that was reported in this study 
appears to be related to enzyme inactivation because 
cross-resistance was not observed with erythromycin 
and chloramphenicol, and, therefore, other lsa and lnu 
genes should be screened to prove this theory.  
These results are consistent with reports of 
emergence of resistance in Listeria spp. and emphasize 
the need for further studies of the genotypic 
characterization of antibiotic resistance in Listeria to 
determine their resistance mechanisms and their 
potential as reservoirs of transferable resistance genes. 
It is also necessary to develop breakpoints for other 
antibiotics in addition to those currently used for 
listeriosis treatment to enhance the interpretation of 
antibiogram results. Based on the results of this study, 
we suggest the possibility of intrinsic daptomycin 
resistance in Listeria spp. This resistance should be 
further studied because of the use of this antibiotic in 
hospital treatments and the implications of its 
resistance mechanisms for other Gram-positive 
bacteria.  
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